PKM2, a splicing variant of pyruvate kinase, is a vital determinant of the cancer metabolism phenotype and selectively enhances proliferative capability for tumor cell growth in vivo.61,62 Therefore, we investigated whether ZMYND11 mitigates the aggressive phenotype of prostate cancer cells induced by PKM2 overexpression. Here, ZMYND11 is linked to prostate carcinoma.